Similar articles

• Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

  Terris MK. Terris MK. Eur Urol. 2009 Feb;55(2):392; discussion 393. doi: 10.1016/j.eururo.2008.02.047. Epub 2008 Mar 11. Eur Urol. 2009. PMID: 18353530 No abstract available.
• Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

  Schröder FH. Schröder FH. Urol Oncol. 2008 Sep-Oct;26(5):533-41. doi: 10.1016/j.urolonc.2008.03.011. Urol Oncol. 2008. PMID: 18774469 Clinical Trial.
• The European Randomized Study of Screening for Prostate Cancer: an update.

  Standaert B, Denis L. Standaert B, et al. Cancer. 1997 Nov 1;80(9):1830-4. Cancer. 1997. PMID: 9351556 Clinical Trial.
• Prostate cancer screening. Why the controversy?

  Walther PJ. Walther PJ. Surg Oncol Clin N Am. 1995 Apr;4(2):315-34. Surg Oncol Clin N Am. 1995. PMID: 7540938 Review.
• Prostate cancer: screening and treatment options.

  Horger DC, Clarke HS. Horger DC, et al. J S C Med Assoc. 2003 Apr;99(4):85-7. J S C Med Assoc. 2003. PMID: 12762154 Review. No abstract available.